Evelyn Peelen, Head of Research, Andreas Muehler, Chief Medical Officer, and Hella Kohlhof, Chief Scientific Officer at Immunic Therapeutics discuss the unmet need for MS treatments that combine neuroprotective, anti-inflammatory, and antiviral properties. For a long time, multiple sclerosis (MS) has been viewed as a disease driven solely by peripheral immune activation—yet most current therapies […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!